Rigel PharmaceuticalsRIGL
About: Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
Employees: 147
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
16% more call options, than puts
Call options by funds: $4.28M | Put options by funds: $3.68M
12.35% less ownership
Funds ownership: 71.53% [Q1] → 59.18% (-12.35%) [Q2]
22% less funds holding
Funds holding: 116 [Q1] → 90 (-26) [Q2]
54% less capital invested
Capital invested by funds: $186M [Q1] → $85.4M (-$100M) [Q2]
67% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 39
96% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 72
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
4 analyst ratings
Cantor Fitzgerald Kristen Kluska 51% 1-year accuracy 50 / 99 met price target | 3%downside $15 | Neutral Reiterated | 20 Sept 2024 |
HC Wainwright & Co. Joseph Pantginis 33% 1-year accuracy 94 / 281 met price target | 270%upside $57 | Buy Reiterated | 5 Sept 2024 |
HC Wainwright & Co. Joseph Pantginis 33% 1-year accuracy 94 / 281 met price target | 270%upside $57 | Buy Reiterated | 3 Sept 2024 |
HC Wainwright & Co. Joseph Pantginis 33% 1-year accuracy 94 / 281 met price target | 270%upside $57 | Buy Maintained | 9 Aug 2024 |
Financial journalist opinion
Based on 3 articles about RIGL published over the past 30 days